EurekAlert! - Infectious and Emerging Diseases This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Significant inequalities observed in popular Liverpool 'mass testing' pilot
(University of Liverpool) A study by the University of Liverpool has shown that while asymptomatic COVID-19 testing in Liverpool was popular, significant inequalities were evident between those who got tested and those who didn't. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 21, 2021 Category: Infectious Diseases Source Type: news

A tapeworm drug against SARS-CoV-2?
(Charit é - Universit ä tsmedizin Berlin) Researchers from the German Center for Infection Research (DZIF) at Charit é - Universit ä tsmedizin Berlin and the University of Bonn have examined the way in which SARS-CoV-2 reprograms the metabolism of the host cell in order to gain an overall advantage. According to their report in Nature Communications, the researchers were able to identify four substances which inhibit SARS-CoV-2 replication in the host cell. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 21, 2021 Category: Infectious Diseases Source Type: news

Microscopy deep learning predicts viral infections
(University of Zurich) When viruses infect cells, changes in the cell nucleus occur, and these can be observed through fluorescence microscopy. Using fluorescence images from live cells, researchers at the University of Zurich have trained an artificial neural network to reliably recognize cells that are infected by adenoviruses or herpes viruses. The procedure also identifies severe acute infections at an early stage. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 21, 2021 Category: Infectious Diseases Source Type: news

RedHill announces presentation of positive oral opaganib phase 2 data in COVID-19
(RedHill Biopharma) RedHill Biopharma Ltd. (Nasdaq: RDHL), a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva ® , ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574). (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 21, 2021 Category: Infectious Diseases Source Type: news

Gene profile in blood predicts risk of poor outcomes, death for patients with COVID-19
(University of South Florida (USF Health)) A blood gene profile associated with a high risk of dying from a severe lung disease can also predict poor outcomes in patients with COVID-19, a multicenter retrospective study led by the University of South Florida Health (USF Health) demonstrated. The risk profile based on 50 genes could help customize how COVID-19 is treated, improve allocation of limited health care resources such as intensive care beds and ventilators, and potentially save lives. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 21, 2021 Category: Infectious Diseases Source Type: news

Antibody disease enhancement of COVID-19 does not appear to occur in animal models
(Duke University Medical Center) In a study published in the journal Cell, Duke investigators demonstrated in mice and monkeys that human antibodies lacked the ability to make SARS-CoV-2 infection worse and, instead, exerted their defensive powers against the infection. The findings help reinforce evidence that antibodies are safe when given as treatments or induced by COVID-19 vaccines. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 21, 2021 Category: Infectious Diseases Source Type: news

Pathogenic bacteria rendered almost harmless
(Universit é de Gen è ve) Pseudomonas aeruginosa can cause chronic infections that are potentially fatal for people with weakened immune systems. In addition, its adaptability and resistance to many antibiotics make infections by P. aeruginosa increasingly difficult to treat. There is therefore an urgent need to develop new antibacterials. Scientists (UNIGE) have identified a previously unknown regulator of gene expression in this bacterium, the absence of which significantly reduces the infectious power of P. aeruginosa and its dangerous nature. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 20, 2021 Category: Infectious Diseases Source Type: news

COVID-19 leads to cognitive and behavioural problems in patients, new study reveals
(emotive) COVID-19 patients suffer from cognitive and behavioural problems two months after being discharged from hospital, a new study presented at the 7th Congress of the European Academy of Neurology (EAN) has found. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 20, 2021 Category: Infectious Diseases Source Type: news

Common antibiotic found useful in accelerating recovery in tuberculosis patients
(National University of Singapore, Yong Loo Lin School of Medicine) Researchers from NUS Yong Loo Lin School of Medicine's Infectious Diseases Translational Research Programme have discovered that the use of a common antibiotic, doxycycline, in combination with TB drug treatment, reduces the size of lung cavities and accelerates markers of lung recovery. This was done in a trial with 30 pulmonary tberculosis patients. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 19, 2021 Category: Infectious Diseases Source Type: news

Assessing Racial, Ethnic disparities in access to COVID-19 vaccination sites
(JAMA Network)What The Study Did:Researchersreviewed access to COVID-19 vaccination sites in Brooklyn, themost populated borough in New York, to better understand disparities in vaccination. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 18, 2021 Category: Infectious Diseases Source Type: news

COVID-19 in Spain
(JAMA Network)What The Study Did:Researchersdescribe the local transmission pattern of SARS-CoV-2 in Valencia, thethird most populatedcity inSpain. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 18, 2021 Category: Infectious Diseases Source Type: news

mRNA vaccine yields full protection against malaria in mice
(Walter Reed Army Institute of Research) WRAIR scientists and partners developed an mRNA vaccine that protects against malaria in animal models. Malaria remains a large public health and economic burden worldwide as well as a danger to deployed Service Members. This vaccine uses mRNA accompanied by a lipid nanoparticle to prompt cells to code for circumsporozoite protein, which then triggers an immune response against malaria. The vaccine achieved high levels of protection in mice, encouraging further development for the novel platform. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 18, 2021 Category: Infectious Diseases Source Type: news

System linked to operational hospitals, shorter lockdowns, lives saved
(University of Texas at Austin) A staged alert system, designed by scientists and public health officials to guide local policies, helped one city prevent hospital surges and long lockdowns, according to new research published in the journal Nature Communications. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 18, 2021 Category: Infectious Diseases Source Type: news

The true spread of SARS-CoV-2 infection is much greater than that observed by capturing only swab-diagnosed COVID-19 cases
(European Alliance of Associations for Rheumatology) COVID-19: The MAINSTREAM project in Lombardy, Italy -- The true prevalence of COVID-19 is still unknown due to the high proportion of subclinical infection. Measuring seroprevalence may be crucial to improve knowledge about the impact of COVID-19 in rheumatic patients. Data shared at the 2021 EULAR congress highlight that the spread of SARS-CoV-2 infection is much greater than that observed by capturing only swab-diagnosed COVID-19 cases, but consistent with healthy population. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 18, 2021 Category: Infectious Diseases Source Type: news

Researchers find losartan is not effective in reducing hospitalization from mild COVID-19
(University of Minnesota Medical School) University of Minnesota Medical School researchers determined that the common blood pressure medication, losartan, is not effective in reducing hospitalization for mildly-ill COVID-19 outpatients. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 18, 2021 Category: Infectious Diseases Source Type: news